IPM clocks Rs 6256 crores in December 2013

The Indian Pharma Market (IPM) grew at 8.2 per cent for the month of December 2013, with the growth driver split between volume and new introductions leading to overall positive growth over December 12.

Amongst the top 10, Emcurestood at 23.5 per cent followed by Sun Pharma 15.4 per cent and Alkem 14.8 per cent. 34 corporates have crossed the growth of IPM for December 2013 amongst top 50. In the list of top 50 corporates, Corona Remedies has the highest growth of 125.1 per cent followed by Eris at 33.4 per cent and Ipca at 29.5 per cent. Amongst the 11-20 ranked companies Aristo shows high growth at 22.3 per cent followed by Glenmark at 19.7 per cent and Microat 19.3 per cent. 33 pharma companies out of top 50 have grown more than IPM growths. Emcureis the 10th biggest corporate on MAT basis while Alembic entered the ` 1000 crore club. Indian companies have grown at 11.3 per cent versus 0.2 per cent for MNCs in December 2013.

Amongst the top 50 MNCs AstraZeneca grew the highest at 17.6 per cent, followed by MSD at 14.2 per cent and Merck at 12.5 per cent.

The DPCO 2013 containing molecules market was at –8.5 per cent whereas the non DPCO market grew by 10.9 per cent resulting in an overall growth of 8.2 per cent for December 2013. The DPCO 2013 portfolio for GSK degrew at 27.5 per cent and Ranbaxy degrew by 14.3 per cent, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio degrowing at 9.6 per cent.

The unit market in both the categories grew leading to overall unit growth of 3.1 per cent. From therapy perspective 10 therapies have outgrown the IPM growth and six therapies have double digit growths. Respiratory market grew up 15.6 per cent, gastrointestinal market moved up 8.7 per cent whereas anti-infectives grew at 3.4 per cent. Anti-diabetic market grew at 13.8 per cent and cardiac at 6.8 per cent in chronic business. Anti-diabetic therapy moves up one rank to be the sixth biggest therapy in the market. Anti-malarials grew up by 23.2 per cent, whereas derma market was at 16.9 per cent.

From a regional perspective, 12 regions have outgrown the IPM growth. Bihar grew highest at 18.8 per cent whereas Karnataka registered 13.6 per cent. One region had negative growth in December 2013.

The biggest molecule Amoxycillin + Clavulanic grew by 6.2 per cent, whereas cefixime degrew at 0.3 per cent. paracetamol grew at 10.5 per cent and azithromycin degrew by -1.4 per cent. The markets of vitamin- D grew by 47.8 per cent, glimepiride + metformin grew at 39.1 per cent, levocetirizine + montelukast by 24.8 per cent, rosuvastain by 21.9 per cent and telmisartan by 16.8 per cent.

Mixtard is the top most brand in IPM with 26.8 per cent growth in December 2013. Amongst the top brands in the IPM, mixtard grew at 26.8 per cent, glycomet – GP grew at 40.7 per cent, skinlite grew at 60 per cent. Over December 2012 brands gaining ranks are Mixtard (+2), Glycomet-GP (+6), Skinlite (+34), Liv-52 (+7), Dexorange (+12), Galvus Met (+20) amongst the top 20 brands in IPM. Corex is the top most brand amongst acute portfolio, whereas mixtard leads amongst chronic brands.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit http://www.aiocd.net